STERIS plc (STE) — Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is balanced-to-slightly-cautious — consensus is a manageable bar, but AST is the swing factor and management has already telegraphed a soft first half.

STERIS heads into its fiscal Q1 2027 print with a consensus that has drifted modestly lower since the May earnings call, reflecting management's own cautious framing around Applied Sterilization Technologies (AST) in the first half of the year. The bar on adjusted EPS is ~$2.51 and revenue ~$1.496B, both slightly below the post-print baseline set in mid-May, suggesting the Street has already absorbed the conservative AST setup. Management's tone on the May call was constructive overall — calling FY2026 a "banner year" and expressing excitement about FY2027 — but explicitly flagged a "slower start in the first half" for AST due to med-tech customer inventory destocking and difficult year-over-year comparisons from double-digit growth in Q1 FY2026. Estimate revisions have been mild and orderly (EPS down ~$0.01 since the post-print baseline), indicating the Street is largely aligned with guidance rather than running ahead of it. The stock has recovered ~15% from its post-earnings lows but remains ~12% below its 6-month high, trading at ~20x NTM P/E — a multiple that has compressed meaningfully and leaves room for re-rating if AST trends better than feared. The key wildcard is whether med-tech customer destocking has run its course: peer commentary from Danaher and Thermo Fisher points to broadly healthy life sciences demand and lower-than-historical inventory levels across the market, which could be an early positive signal for AST's trajectory into the second half.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar on revenue and EPS, with AST segment revenue the bigger swing factor given management's explicit caution. Healthcare Services remains the most predictable line.

Table 1 — Current Quarter Snapshot (Q1 FY2027, quarter ending June 30, 2026)

¹ Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 4, 2026.

Table 2 — Beat/Miss History: Adjusted EPS (Last 8 Quarters)

Pattern: STE has a mixed but generally constructive beat/miss history — 5 beats or in-lines out of the last 7 reported quarters, with misses concentrated in periods of macro or weather-driven disruption (Q3 FY2025 and Q4 FY2026). The Q4 FY2026 miss was modest and driven by AST weather disruption, not structural demand weakness. Source: Visible Alpha Consensus and Actuals Data.

Table 3 — Beat/Miss History: Total Revenue (Last 7 Reported Quarters)

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: No post-earnings guidance revisions have been issued since the May 12 call. FY2027 guidance stands as initially provided, with tone constructive overall but explicitly cautious on AST in H1.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted modestly lower since the post-print baseline, tracking management's conservative H1 framing. The gap between consensus and the top of guidance represents cushion rather than risk — the Street is not running ahead of the company.

¹ Source: Visible Alpha Consensus and Actuals Data. Post-earnings baseline uses consensus as of May 18, 2026 (approximately 5 trading days after the May 11, 2026 earnings release).

Commentary: The revision picture is remarkably stable — estimates have barely moved since the post-print baseline, with EPS down just $0.01 and revenue essentially flat. This tells us the Street has fully digested management's H1 AST caution and is not pricing in incremental risk. The FY2027 EPS consensus of $11.17 sits at the low end of the $11.10–$11.30 guidance range, leaving room for upward revision if AST trends better than feared in H2 or if tariff refunds (not included in guidance) materialize.

5. Stock Performance

Key Takeaway: The stock's +15% recovery since the May 11 earnings date has been driven primarily by multiple re-expansion, not estimate revisions — the NTM EV/EBITDA multiple expanded ~5.7% over the past month. The 6-month picture tells a different story: STE is still -12% from its 6-month high, with multiple compression of ~16% over that window dominating the return.

Since the May 11, 2026 earnings date, STE has risen from $201.85 to $232.85 (as of August 5, 2026), a gain of approximately +15.4%, outperforming the Health Care Select Sector ETF (XLV, +13.3%) and the S&P 500 (+4.3%) over the same period. The stock's recovery was not driven by estimate revisions (which were essentially flat) but rather by multiple re-expansion as the market gained confidence in the FY2027 guidance and the new $1B buyback authorization. The NTM P/E has expanded from ~18x at the post-earnings trough to ~20x currently, still well below the 6-month-ago level of ~24x. A notable acceleration occurred in late July (July 28–29), when STE surged ~10% in two sessions, coinciding with broader healthcare sector strength and positive peer read-throughs from Thermo Fisher and GE HealthCare. The sector ETF used is XLV (Health Care Select Sector SPDR), which is appropriate for STE's diversified healthcare/life sciences profile.

Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition (Implied). STE indexed to 100 at May 11, 2026 close of $201.85.

6. Material News & Developments

Key Takeaway: No company-specific negative developments since the May earnings call. The most important post-earnings development is the new $1B buyback authorization and the board appointment of Pierre Boulud, which reinforce capital return and governance credibility heading into the print.

• May 11, 2026 — New $1B Share Buyback Authorization Announced. Board approved a new $1 billion share repurchase program replacing the prior authorization, with management committing to $200–$300M in annual buybacks. This was a key positive catalyst on earnings day and drove the stock's sharp recovery from the modest Q4 miss. Implication: Signals management confidence in FCF generation and provides a durable EPS tailwind.
• May 7, 2026 — Board Appointment: Pierre Boulud (bioMérieux CEO) Added. STERIS appointed Pierre Boulud, CEO of bioMérieux, to its expanded board. Implication: Adds deep life sciences and diagnostics expertise; reinforces STERIS's strategic positioning in the Life Sciences segment.
• May 12, 2026 — FY2027 Guidance Issued at or Above Prior Consensus. Adjusted EPS guidance of $11.10–$11.30 (9–11% growth) came in at or above prior Street expectations, with tariff spend modeled flat YoY at $60–$65M. Implication: Removed the tariff escalation overhang that had weighed on the stock through FY2026.
• May 12, 2026 — New Sterility Assurance Manufacturing Plant Announced (Mentor, Ohio). STERIS announced a ~$60M investment over two years to build a new state-of-the-art sterility assurance manufacturing center of excellence, expected operational by late calendar 2027. Implication: Supports long-term demand for a high-margin product line; included in the $375M CapEx guidance.
• July 27, 2026 — Q1 FY2027 Earnings Call Announcement. STERIS confirmed earnings release after market close August 5, 2026, with conference call at 9:00 a.m. ET on August 6, 2026. No pre-announcement or guidance update was issued alongside this notice. Implication: Absence of a pre-announcement is a mild positive signal — no need to warn on results.
• Ongoing — Tariff Policy Uncertainty. The Supreme Court struck down IEEPA-based tariffs in February 2026; new Section 301 tariffs of 10–12.5% on 60 trading partners took effect July 24–25, 2026. STERIS modeled tariff spend flat YoY in FY2027 guidance and excluded any USMCA assumptions. Implication: New tariff regime could create incremental headwinds or tailwinds depending on STERIS's supply chain exposure; management will likely be asked for an updated tariff assessment on the call.
• July 28–29, 2026 — Positive Peer Read-Throughs (TMO, GEHC, SYK, BSX). Multiple healthcare and life sciences peers reported strong Q2 results with raised guidance, driving a broad sector rally. STE surged ~10% over July 28–29 in sympathy. Implication: Positive read-through for STERIS's Healthcare and Life Sciences segments; see Peer Commentary section for detail.

7. Peer Commentary / Current-Quarter Read-Through

Key Takeaway: Forward-looking commentary from Thermo Fisher (TMO), Danaher (DHR), and Intuitive Surgical (ISRG) — all reporting in the last 60 days — paints a broadly constructive picture for STERIS's Life Sciences and Healthcare segments in the current reporting quarter (calendar Q3 2026 / STE fiscal Q1 FY2027). The most relevant signal is the strengthening pharma/biotech demand environment and lower-than-historical inventory levels across the market, which could support an AST recovery earlier than feared. Caveats on exposure overlap are noted for each peer.

Methodology Note: Only forward-looking commentary from peer earnings calls in the last 60 days that explicitly addresses conditions in the current reporting period (calendar Q3 2026 / STE fiscal Q1 FY2027) or the remainder of calendar 2026 is included below. Retrospective commentary on peers' own reported quarters is excluded.

7.1 Thermo Fisher Scientific (TMO) — Reported July 23, 2026

Relevance to STE: TMO is a leading life sciences tools and services company with significant pharma/biotech customer overlap. Most relevant to STERIS's Life Sciences segment and, indirectly, AST (which sterilizes products for pharma/biotech customers). Less directly relevant to STERIS's Healthcare segment (hospital procedure volumes, capital equipment).

• Raised full-year 2026 guidance and improved H2 outlook. TMO raised revenue guidance to $47.4–$48.1B (6–8% reported growth) and increased full-year organic growth expectation to ~4%, now expected at the upper end of the 3–4% range. Adjusted EPS guidance raised to $24.93–$25.33, a $0.25 increase at the midpoint. Read-through: A major life sciences player raising guidance and improving its H2 outlook is a positive signal for the demand environment that STERIS's Life Sciences segment serves.
• Pharma and biotech demand strengthening into H2. CEO Marc Casper stated "customer activity across our end markets continued to strengthen" and highlighted "good momentum continues in pharma, but also biotech." Bioproduction had an "excellent quarter" with demand "strong" and capacity being increased. Large pharma customers described as having "a lot of excitement about their pipelines" and a "quite positive tone." Read-through: Directly positive for STERIS's Life Sciences segment, which serves pharma/biotech manufacturing and research. Strengthening bioproduction demand supports AST sterilization volumes for pharma customers.
• H2 organic growth expected to step up to ~4% (from 3% in H1). TMO guided for both Q3 and Q4 to show similar organic revenue growth of ~4%, with Q3 adjusted EPS expected to be $0.35–$0.40 higher than Q2. Read-through: Consistent acceleration into H2 supports STERIS management's own framing of H2 AST recovery after a softer H1.
• Clinical research authorizations strong; 6-month lag to revenue. TMO's PPD clinical research business had an "excellent quarter" with "strong organic growth and authorizations." Biotech activity has been picking up in authorizations "for a few quarters now" with a "six month lag or so from authorizations to revenue." Read-through: Strong authorization trends in clinical research suggest sustained demand for sterilization services tied to clinical-stage drug manufacturing, a positive for STERIS's AST and Life Sciences segments in H2 FY2027.
• Exposure caveat: TMO's business is primarily research tools, diagnostics, and CDMO services. The read-through to STERIS is strongest for the Life Sciences segment and indirect for Healthcare (hospital procedure volumes, capital equipment). TMO's commentary does not address medtech customer inventory dynamics, which is the key near-term risk for STERIS's AST segment.

7.2 Danaher (DHR) — Reported July 20–21, 2026

Relevance to STE: DHR operates in life sciences tools, diagnostics, and bioprocessing (Cytiva). Relevant to STERIS's AST segment (bioprocessing sterilization demand) and Life Sciences segment. Less directly relevant to Healthcare (hospital procedures). DHR's stock fell ~11–14% on earnings day despite a beat, due to softer-than-expected Q3 core revenue growth guidance — a cautionary signal for the pace of life sciences recovery.

• Q3 2026 core revenue growth guided at 2–3% (ex-respiratory: ~5%). DHR guided Q3 core revenue growth of approximately 2–3%, including a ~250 bps headwind from respiratory testing. Excluding respiratory, core growth is projected at ~5%, an acceleration versus Q2. The company expects to exit Q4 at a mid-single digit core revenue growth rate. Read-through: The ex-respiratory acceleration to ~5% in Q3 is a positive signal for underlying life sciences demand. However, the headline 2–3% guidance disappointed the market, suggesting the pace of recovery is more gradual than hoped — a mild caution for STERIS's AST H2 recovery thesis.
• Life sciences markets recovering faster than initial expectations. DHR's updated outlook reflects "higher anticipated core revenue growth in our life sciences segment, as we expect these markets to recover faster than our initial expectations." Large pharma and biopharma customers "progressing back to normal" and biotech demand benefiting from "a more favorable funding environment." Read-through: Faster-than-expected life sciences recovery is a positive for STERIS's Life Sciences segment and, over time, for AST as pharma manufacturing volumes grow.
• Bioprocessing: underlying demand healthy despite timing shifts. DHR noted "mid-teens order growth in both consumables and equipment" in bioprocessing, with underlying demand "remained very healthy" despite ~$100M+ in large chromatography resin shipments shifting from Q2/Q3 into 2027 due to customer production schedule changes and site readiness. DHR believes "we're in the early innings here of a multi-year CapEx cycle" driven by biologic therapeutics growth and reshoring. Read-through: The multi-year biopharma CapEx cycle and reshoring dynamic are structurally positive for STERIS's AST capacity and Life Sciences capital equipment. The timing shifts in DHR's bioprocessing revenue signal potential lumpiness in large project timelines, which could affect STERIS's AST for large-scale sterilization projects.
• Inventory levels broadly lower than historical norms. DHR noted that "inventory levels more broad based in the market are actually quite a bit lower than they have been in prior years," attributed to significantly shorter lead times allowing safety stocks to come down. Read-through: This is a key positive read-through for STERIS's AST segment: if broad market inventory levels are already lean, the risk of further destocking by med-tech customers (STERIS's primary AST concern) may be more limited than feared. This could support an earlier-than-guided AST recovery.
• Hospital acquired infection assays growing low double digits. DHR's Cepheid non-respiratory revenue grew low double digits, led by hospital acquired infection and sexual health assays. Read-through: Continued investment in hospital infection prevention is directly relevant to STERIS's core Healthcare market, suggesting robust underlying demand for infection prevention products and services.
• Exposure caveat: DHR's bioprocessing commentary (chromatography resins) is specific to drug manufacturing inputs, not finished product sterilization. The customer timing dynamics causing DHR's revenue shifts may not directly translate to STERIS's sterilization services. DHR's academic/government exposure is <5% of revenue, limiting read-through to that sub-segment.

7.3 Intuitive Surgical (ISRG) — Reported July 16, 2026

Relevance to STE: ISRG is the leading robotic surgery platform. Relevant to STERIS's Healthcare segment (hospital procedure volumes, capital equipment demand, infection prevention). ISRG's procedure growth is a leading indicator of surgical volume trends that drive demand for STERIS's sterilization and infection prevention products in hospitals.

• Full-year 2026 Da Vinci procedure growth guidance maintained at 13.5–15.5%, closer to midpoint. ISRG maintained its full-year procedure growth forecast, with expectation to be closer to the midpoint of the range. Primary growth drivers remain general surgery in the U.S. and procedures outside urology internationally. Read-through: Stable, mid-teens procedure growth is a positive backdrop for STERIS's Healthcare segment, which benefits from high surgical volumes driving demand for sterilization services, consumables, and capital equipment.
• U.S. procedure growth moderated to 12% in Q2 (from 14% in Q1); some ACA and GLP-1 headwinds. U.S. Da Vinci procedure growth moderated from 14% in Q1 to 12% in Q2, attributed to a modest adverse impact from ACA premium subsidy expiration and GLP-1-driven bariatric case declines (high single digits). Benign procedures showed a slight moderation in growth rate. Read-through: The moderation in U.S. procedure growth is a mild caution for STERIS's Healthcare services revenue, which is tied to procedure volumes. However, the moderation is modest and management has not seen ACA trends impact its capital pipeline.
• U.S. capital environment stable; 70% of systems under leasing arrangements. ISRG placed 468 Da Vinci systems in Q2 (+18% YoY), with U.S. capital performance "strong" (267 systems, +24% YoY). The U.S. capital environment has been "stable for some time" with ~70% of systems under leasing arrangements providing flexibility. Read-through: Strong capital equipment placement by ISRG is a positive for STERIS's Healthcare capital equipment segment, as new robotic surgery installations require STERIS's sterilization and infection prevention infrastructure.
• Japan: new reimbursement policies for robotic surgery effective June 1; cautious optimism. New Japanese policies supporting robotic surgery went into effect June 1, including reimbursement for additional procedures and economic incentives for higher utilization. ISRG expressed "cautious tone of optimism" but noted procedure adoption will take time. Read-through: Positive for STERIS's international Healthcare segment over the medium term as robotic surgery adoption expands in Japan.
• Extended use instrument program planned for H1 2027 — potential headwind to STERIS consumables. ISRG plans to introduce updated instruments with increased useful lives and lower customer cost per use in H1 2027, targeting high-volume benign procedures and cost-constrained markets. Read-through: This is a mild potential negative for STERIS's Healthcare consumables segment over time, as longer instrument useful lives could reduce sterilization cycle frequency for ISRG instruments. However, the impact is likely modest and progressive rather than a step-change.
• Exposure caveat: ISRG's commentary is specific to robotic surgery and does not address broader hospital capital spending, non-robotic procedure volumes, or AST/Life Sciences dynamics. The read-through to STERIS is most direct for Healthcare services and consumables, and less so for AST or Life Sciences.

7.4 Additional Peer Signals (Last 60 Days)

8. Insider Transaction Activity

Key Takeaway: All insider transactions since the last earnings call are 10b5-1 planned sales — no discretionary open-market selling or buying. The CEO's planned sales were pre-scheduled and represent a small fraction of holdings. Nothing here signals unusual concern or conviction.

Source: SEC Form 4 Filings (Insider Transaction Data). Open-market transaction window: May 11, 2026 – August 4, 2026. No open-market purchases or discretionary sales were identified in this period.

9. Key Risks and Questions for the Call

Key Risks

• AST Destocking Persists Longer Than Guided. Management guided for a "slower start in H1" for AST, but if med-tech customer inventory management extends into Q2 FY2027 (September quarter), the H2 recovery thesis could be pushed out, pressuring the FY2027 7–8% AST growth target. DHR's commentary on customer timing dynamics in bioprocessing is a cautionary parallel.
• Tariff Policy Uncertainty — New Section 301 Regime. New 10–12.5% tariffs on 60 trading partners took effect July 24–25, 2026. STERIS modeled tariff spend flat YoY at $60–$65M in FY2027 guidance, but the new tariff regime could create incremental headwinds if STERIS's supply chain has meaningful exposure to affected countries. USMCA review outcome is also a watch item.
• Healthcare Services Growth Normalization. Management proactively guided for Healthcare services growth to moderate from teens to high single digits as labor cost inflation moderates. If procedure volumes soften (ACA subsidy expiration, GLP-1 impact on bariatric cases per ISRG commentary), the moderation could be sharper than guided.
• Multiple Compression Risk. STE trades at ~20x NTM P/E, still below its 6-month-ago level of ~24x. If Q1 results disappoint on AST or if management's H2 recovery commentary is less confident than expected, the multiple could compress further, amplifying the stock's downside.
• Life Sciences Capital Equipment Lumpiness. Life Sciences capital equipment backlog entered FY2027 at "just under $100M" — solid but not exceptional. DHR's experience with large biopharma project timing shifts signals that Life Sciences capital revenue can be lumpy quarter-to-quarter.

Key Questions for the Call

1. AST Trajectory: Can you provide more granularity on where med-tech customer inventory levels stand today versus 90 days ago? Are you seeing any early signs of destocking abating, or is the H1 caution still fully intact?
2. Tariff Update: With new Section 301 tariffs taking effect July 24–25, how does your current tariff spend tracking compare to the $60–$65M FY2027 assumption? Have you seen any tariff refunds materialize that were excluded from guidance?
3. USMCA: You assumed USMCA would remain "stagnant" in your guidance. Has there been any update on the USMCA review process, and what is the potential impact if it moves unfavorably?
4. Healthcare Services Pricing: With labor cost inflation moderating, how is the pricing dynamic evolving in Healthcare services? Are you seeing any pushback from hospital customers on service contract renewals?
5. Life Sciences Pharma Reshoring: You cited pharma reshoring and East Coast/Carolina builds as Life Sciences tailwinds. Can you size the pipeline of new facility projects and the expected timing of revenue contribution?
6. Buyback Cadence: How much of the $200–$300M annual buyback commitment has been deployed in Q1 FY2027? Are you on track for the full-year range?
7. Ohio Plant Progress: What is the current status of the Mentor, Ohio sterility assurance manufacturing plant? Is the late calendar 2027 operational timeline still intact?
8. AI Investment: You mentioned a multiyear AI project to improve service workflows in Healthcare and Life Sciences. What is the expected incremental OpEx impact in FY2027, and when do you expect to see productivity benefits?